isoxazoles has been researched along with cladribine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heath, M; Raugi, GJ | 1 |
| Burton, JM; O'Connor, P | 1 |
| Gonsette, RE | 1 |
3 review(s) available for isoxazoles and cladribine
| Article | Year |
|---|---|
Evidence-based evaluation of immunomodulatory therapy for the cutaneous manifestations of lupus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimalarials; Azathioprine; Cladribine; Cyclophosphamide; Cyclosporine; Evidence-Based Medicine; Humans; Immunoglobulin G; Immunologic Factors; Immunotherapy; Isoxazoles; Leflunomide; Lupus Erythematosus, Cutaneous; Methotrexate; Mycophenolic Acid; Rituximab; Tacrolimus; Thalidomide | 2004 |
Novel oral agents for multiple sclerosis.
Topics: Administration, Oral; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Cladribine; Clinical Trials as Topic; Dimethyl Fumarate; Fingolimod Hydrochloride; Fumarates; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Isoxazoles; Leflunomide; Minocycline; Multiple Sclerosis; Mycophenolic Acid; Propylene Glycols; Pyridones; Quinolones; Sphingosine | 2007 |
Compared benefit of approved and experimental immunosuppressive therapeutic approaches in multiple sclerosis.
Topics: Antibodies, Monoclonal; Cladribine; Cyclophosphamide; Drug Delivery Systems; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Isoxazoles; Ligands; Mitoxantrone; Multiple Sclerosis; Propylene Glycols; Sphingosine | 2007 |